| Cat.No. | Name | Information |
|---|---|---|
| M1637 | ABT-263 | ABT-263 (Navitoclax) is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x (L), and Bcl-w. |
| M2017 | ABT-199 (Venetoclax) | ABT-199 is a highly potent, orally bioavailable and BCL-2 inhibitor. ABT-199 is the first inhibitor targeting Bcl-2 and PPI. |
| M5273 | S63845 | S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM. |
| M13528 | AZD-5991 | AZD-5991 is a potent and selective Mcl-1 inhibitor with an IC50 of 0.7 nM in FRET assay and a Kd of 0.17 nM in surface plasmon resonance (SPR) assay. |
| M13526 | A-1155463 | A-1155463 is a highly potent and selective BCL-XL inhibitor with an EC50 of 70 nM in Molt-4 cell. |
| M28240 | AZD4320 | AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. |
| M28068 | A-1211212 | A-1211212 (BCL2-IN-1) is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM. |
| M25493 | MSN-50 | MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection. |
| M22513 | Mcl-1 inhibitor 6 | Mcl-1 inhibitor 6 is an orally active, selective myeloid cell leukemia 1 (Mcl-1) protein inhibitor with a Kd of 0.23 nM and a Ki of 0.02 μM. Mcl-1 inhibitor 6 possesses superior selectivity over other Bcl-2 family members (Bcl-2, Bcl2A1, Bcl-xL, and Bcl-w, Kd>10 μM). |
| M22511 | UBX1325 | UBX1325 is an Bcl-xL inhibitor that promotes apoptosis in senescent cells. UBX1325 is a potent anti-aging agent that can be used in studies of age-related eye diseases such as diabetic macular oedema (DME), age-related macular degeneration (AMD) and diabetic retinopathy (DR). |
| M21157 | CCT369260 | CCT369260 is an orally active, B-cell lymphoma 6 (BCL6) inhibitor with antitumor activity and an IC50 value of 520 nM. |
| M21125 | ABBV-167 | BCL-2 inhibitor prodrug (ABBV-167) is a phosphate prodrug of venetoclax with the potential ability to study chronic lymphocytic leukemia (CLL). |
| M20819 | Obatoclax (GX15-070) | Obatoclax (GX15-070) is an antagonist of Bcl-2 with an Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. |
| M20636 | BI-3812 | BI-3812 is a highly potent and efficacious BCL6 inhibitor probe compound with an IC50 less than 3 nM. |
| M13534 | WEHI-539 hydrochloride | WEHI-539 hydrochloride is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM. |
| M13533 | S55746 hydrochloride | S55746 hydrochloride (BCL201 hydrochloride) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 hydrochloride (BCL201 hydrochloride) has antitumor activity with low toxicity. |
| M13532 | S55746 | S55746 (BCL201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BCL201) has antitumor activity with low toxicity. |
| M13531 | Dehydrocorydaline nitrate | Dehydrocorydaline nitrate (13-Methylpalmatine nitrate) is an alkaloid. |
| M13530 | Dehydrocorydaline chloride | Dehydrocorydaline chloride (13-Methylpalmatine chloride) is an alkaloid that regulates protein expression of Bax, Bcl-2; activates caspase-7, caspase-8, and inactivates PARP. Dehydrocorydaline chloride elevates p38 MAPK activation. Dehydrocorydaline chloride has anti-inflammatory and anti-cancer activities. |
| M13527 | (R)-(-)-Gossypol acetic acid | (R)-(-)-Gossypol acetic acid (AT-101 (acetic acid)) is the levorotatory isomer of a natural product Gossypol. |
| M13525 | (S)-Gossypol (acetic acid) | (S)-Gossypol is the isomer of a natural product Gossypol. (S)-Gossypol binds to the BH3-binding groove of Bcl-xL and Bcl-2 proteins with high affinity. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
